1081-04-5

Basic information

• Product Name: 5-BROMO-1H-INDAZOLE-3-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: ETHYL 5-BROMO-1H-INDAZOLE-3-CARBOXYLATE;5-BROMO-1H-INDAZOLE-3-CARBOXYLIC ACID ETHYL ESTER;ethyl 5-broMo-1H-indazol-3-carboxylate;1H-Indazole-3-carboxylic acid, 5-broMo-, ethyl ester;5-BROMO-1H-INDAZOLE-3-CARBOXYLIC ACID ETHYL ESTE
• CAS NO: 1081-04-5
• Molecular Formula: C₁₀H₉BrN₂O₂
• Molecular Weight: 269.09
• Mol File: 1081-04-5.mol
• Article Data: 3

Chemical Properties

• Melting Point: 142 °C
• Boiling Point: 406.4 °C at 760 mmHg
• Flash Point: 199.6 °C
• Appearance: /
• Density: 1.624 g/cm³
• Vapor Pressure: 8.15E-07mmHg at 25°C
• Refractive Index: 1.653
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 10.67±0.40(Predicted)
• CAS DataBase Reference: 5-BROMO-1H-INDAZOLE-3-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-1H-INDAZOLE-3-CARBOXYLIC ACID ETHYL ESTER(1081-04-5)
• EPA Substance Registry System: 5-BROMO-1H-INDAZOLE-3-CARBOXYLIC ACID ETHYL ESTER(1081-04-5)

Safety Data

• Hazardous Substances Data: 1081-04-5(Hazardous Substances Data)

Usage

General Description

5-BROMO-1H-INDAZOLE-3-CARBOXYLIC ACID ETHYL ESTER is a chemical compound with the molecular formula C10H8BrNO2. It is an ethyl ester derivative of 5-bromo-1H-indazole-3-carboxylic acid, which is a heterocyclic compound containing an indazole ring with a carboxylic acid group at the 3-position. This chemical is commonly used in organic synthesis and pharmaceutical research as a building block for the preparation of various indazole derivatives with potential biological activities. Its unique structure and reactivity make it a valuable intermediate in the synthesis of bioactive compounds and pharmaceuticals.

InChI:InChI=1/C10H9BrN2O2/c1-2-15-10(14)9-7-5-6(11)3-4-8(7)12-13-9/h3-5H,2H2,1H3,(H,12,13)

Upstream product

• 4498-67-3 1H-Indazole-3-carboxylic acid 
• 4498-68-4 ethyl 1H-indazole-3-carboxylate 

Downstream Products

• 705264-93-3 (5-bromo-1H-indazol-3-yl)methanol 
• 1448314-55-3 5-bromo-1-(3-methylbenzoyl)-1H-indazole-3-carboxylic acid ethyl ester 
• 1448314-56-4 5-bromo-1-(3-methoxybenzoyl)-1H-indazole-3-carboxylic acid ethyl ester 
• 1428066-10-7 ethyl 5-bromo-1-trityl-1H-indazole-3-carboxylate 

Relevant articles and documents

METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.